腋窝淋巴结阳性乳腺癌中多西他赛序贯吡柔比星/环磷酰胺应用的临床观察被引量：1

The Clinical Use of Docetaxel Followed by Doxorubicin and Cyclophosphamide in Axillary Lymph Node Positive Breast Cancer

下载PDF

导出

摘要目的观察多西他赛序贯吡柔比星/环磷酰胺在腋窝淋巴结阳性乳腺癌辅助化疗中的应用。方法收集41例病理证实的腋窝淋巴结阳性的乳腺癌术后患者,予多西他赛序贯吡柔比星/环磷酰胺治疗,记录和分析治疗过程发生的毒不良反应。结果全组41例病例,有37例完成化疗,血液学毒性主要表现为白细胞的下降;非血液学毒性主要为脱发和胃肠道反应;其他包括转氨酶升高、心脏毒性及周围神经毒性等,经对症治疗后,所有毒不良反应均能缓解。结论多西他赛序贯吡柔比星/环磷酰胺在腋窝淋巴结阳性乳腺癌辅助化疗的临床应用中不良反应可耐受。 Objective To evaluate the clinical use and toxicities of doeetaxel followed by doxorubicin and cyclophosphamide as adjuvant chemotherapy for axillary lymph node positive breast cancer. Methods 41 patients with histologically proven, axillary lymph node positive breast cancer were enrolled into the study, and treated with docetaxel followed by doxorubicin and cyclophosphamide. All the toxicities produced by the regimen were recorded. Results 37 of 41 patients received all planed treatment. Neutropenia was the most frequent hematologic toxicity, and the most frequent nonhematologic toxicities included alopecia and gastrointestinal reaction, the other nonhematologic toxicities were hepatotoxicity, cardiotoxicity and peripheral neuropathy. Conclusions Toxicities of docetaxel followed by doxorubicin and cyclophosphamide as adjuvant chemotherapy for axillary lymph node positive early breast cancer were tolerable, and the regimen may be used in patients with axillary lymph node positive breast cancer.

作者李春鸣余更生林秀欣周颖

机构地区江门市中心医院肿瘤科

出处《中国医药指南》 2012年第32期32-34,共3页 Guide of China Medicine

关键词腋窝淋巴结阳性乳腺癌多西他赛蒽环类辅助化疗 Axillary lymph node positive breast cancer Docetaxel Anthracycline Adjuvant chemotherapy

分类号 R737.9 [医药卫生—肿瘤]

引文网络
相关文献

参考文献9

1Anton A,Hornedo J,Lluch A,et al.A phase II study of sequentialdocetaxel followed by doxorubicin/cyclophosphamide as first-linechemotherapy for metastatic breast cancer[J].Clin Breast Cancer,2003,4(4):286-291.
2Gradishar WJ,Wedam SB,Jahanzeb M,et al.Neoadjuvant docetaxelfollowed by adjuvant doxorubicin and cyclophosphamide inpatients with stage III breast cancer[J].Ann Oncol,2005,16(8):1297-1304.
3Wildiers H,Dirix L,Neven P,et al.Delivery of adjuvant sequentialdose-dense FEC-Doc to patients with breast cancer is feasible,butdose reductions and toxicity are dependent on treatment sequence[J].Breast Cancer Res Treat,2009,114(1):103-112.
4Guo B,Villeneuve DJ,Hembruff SL,et al.Cross-resistance studiesof isogenic drug-resistant breast tumor cell lines support recentclinical evidence suggesting that sensitivity to paclitaxel may bestrongly compromised by prior doxorubicin exposure[J].BreastCancer Res Treat,2004,85(1):31-51.
5Norton L.A Gompertzian model of human breast cancer growth[J].Cancer Res,1988,48(24 Pt 1):7067-7071.
6Citron ML,Berry DA,Cirrincione C,et al.Randomized trial of dose-dense versus conventionally scheduled and sequential versusconcurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer:First report of Intergroup trial C9741/Cancer and Leukemia Group B trial 9741[J].J Clin Oncol,2003,21(8):1431-1439.
7Bria E,Nistico C,Cuppone F,et al.Benefit of taxanes as Adjuvant chemotherapy for early breast cancer:pooled analysis of15500 patients[J].Cancer,2006,106(11):2337-2344.
8Jones SE,Erban J,Overmoyer B,et al.Randomized phase III study of docetaxel compared with paclitaxel in metastatic Breast cancer[J].J Clin Oncol,2005,23(24):5542–5551.
9Puhalla S,Mrozek E,Young D,et al.Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer[J].J Clin Oncol,2008,6(10):1691-1697.